Anti-HER-2/neu antibody induces apoptosis in HER-2/neu overexpressing breast cancer cells independently from p53 status

British Journal of Cancer

Volumn 85, Issue 11, 2001, Pages 1764-1770

  Brodowicz, T ^a   Kandioler, D ^a   Tomek, S ^a   Ludwig, C ^a   Rudas, M ^a   Kunstfeld, R ^a   Koestler, W ^a   Hejna, M ^a   Budinsky, A ^a   Wiltschke, C ^a   Zielinski, C C ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Apoptosis; Bcl 2; Breast cancer; HER 2 neu; p53

Indexed keywords

HER 2 PROTEIN ANTIBODY; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; DNA FRAGMENTATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035977189     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2197     Document Type: Article

References (58)

1. Specific p53 mutations are associated with de nova resistance to doxorubicin in breast cancer patients
2. Bcl-2 inhibits p53 nuclear import following DNA damage
3. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
4. γ-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53
5. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro
6. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids
7. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
8. Induction of the growth inhibitor IGE-binding protein 3 by p53
9. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
10. Bcl-2 blocks p53-dependent apoptosis
11. Efficacy and safety of herceptin™ (humanized anti-Her2 antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer
12. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
13. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
14. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid
15. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts
16. Signal transduction pathways that regulate cell survival and cell death
17. The regulation of E2F by pRB-family proteins
18. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
19. Weekly herceptin ∓ 1 hour taxol: Phase II study in Her2 overexpressing and non-overexpressing metastatic breast cancer
20. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
21. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice
22. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists
23. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
24. Bcl-2 functions in an antioxidant pathway to prevent apoptosis
25. A novel p53-inducible gene PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis
26. Reactive oxygen species are downstream mediators of p53-dependent apoptosis
27. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
28. Participation of p53 in the cellular response to DNA damage
29. Some recent advances in preclinical aspects of treating cancer by inhibition of tumor angiogenesis
30. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics
31. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
32. The proto-oncogene bcl-2 and its role in regulating apoptosis
33. P53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines
34. erbB2
35. The p53-binding protein 53BP2 also interacts with bcl2 and impedes cell cycle progression at G2/M
36. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-her2 monoclonal antibody herceptin in Her2-overexpressing metastatic breast cancer
37. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
38. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
39. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
40. Bcl-2 and the regulation of programmed cell death
41. Dysregulation of apoptosis in cancer
42. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
43. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells
44. The cellular response to p53: The decision between life and death
45. Addition of hereeptin™ to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
46. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2
47. Molecular characterization of mitochondrial apoptosis-inducing factor
48. Apoptosis in the pathogenesis and treatment of disease
49. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
50. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression
51. Loss of normal p53 function confers to sensitization to Taxol by increasing G2/M arrest and apoptosis
52. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway
53. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
54. p21 is a universal inhibitor of cyclin kinases
55. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
56. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
57. Heterodimerization-independent functions of cell death regulatory, proteins bax and bcl-2 in yeast and mammalian cells
58. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells